https://www.selleckchem.com/pr....oducts/s-adenosyl-l-
China is uniquely positioned to recruit sufficiently large sample sizes of treatment-naïve OCD patients to compare different pharmacotherapy options; data from the proposed trial promises to help inform current clinical practice guidelines by providing important information about optimal pharmacotherapy choice for those who demonstrate no response or response but no remission to first line pharmacotherapy. The trail was registered on 27 August 2020 in ClinicalTrials.gov (https//register.clinicaltrials.gov/) (NCT0453995
Like
Comment
Share
